Chemistry:Mitumomab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | GD3 ganglioside |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Mitumomab (BEC-2) is a mouse anti-BEC-2 monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. It was developed by ImClone and Merck.[1]
The first phase III clinical trial began in 1998.[2][3] In 2005 and again in 2008, results were published showing no benefit to patients receiving mitumomab and BCG.[4][5]
See also
- Anti-ganglioside antibodies
References
- ↑ "Mitumomab - AdisInsight". 2005-06-13. http://adisinsight.springer.com/drugs/800003245.
- ↑ Clinical trial number NCT00037713 for "Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG" at ClinicalTrials.gov
- ↑ Clinical trial number NCT00006352 for "Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer" at ClinicalTrials.gov
- ↑ "Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer". European Journal of Cancer 44 (15): 2178–84. October 2008. doi:10.1016/j.ejca.2008.06.036. PMID 18676140.
- ↑ "Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)". Journal of Clinical Oncology 23 (28): 6854–64. October 2005. doi:10.1200/JCO.2005.17.186. PMID 16192577.
 |  |
